## The Road to COVAX AMC Resource Mobilization



18 January 2022

## **Civil Society Briefing Agenda**

- Welcome & Introduction
- COVAX looking back
- COVAX today
- Breaking COVID-19
- Q&A

Presentation by:

Marie-Ange Saraka Yao, Managing Director, RM, PSP & Innovative Finance, Gavi, the Vaccine Alliance Guillaume Grosso, Director, Sovereign & Private Sector Engagement, Donor Relations & Campaigns, Gavi, the Vaccine Alliance




### The Gavi COVAX AMC was established within COVAX to provide an essential lifeline to 92 eligible lower-income economies

- The first COVAX-supplied vaccine doses were administered in an AMC country on 16 January; just 39 days after the first dose of a COVID-19 vaccine was administered in a high-income country, a historic first.
- Despite great efforts, at each stage of the journey in 2021, there have been roadblocks in the path of the world's poorest.
- Higher-income countries took most early doses. Export restrictions, manufacturing challenges and delays to regulatory approvals further restricted supplies to AMC economies.
- At the end of 2021 that tide started to turn.




#### COVAX has delivered more than a billion doses of life-saving COVID-19 vaccines to 144 participating economies in under one year





## COVAX has built a diverse portfolio of 1.7bn doses, but a key lesson is the need for upfront cash to secure deals



#### Tremendous progress has been achieved through work together

Partner engagement

**High-level champion engagement** 

**Grassroots advocacy** 

#### We cannot risk prolonging this pandemic a day longer. With Jeremy Farrar 🧭 nough global support for COVAX, we can ensure vaccines JeremyFarra are accessible to those that need them the most - across Wonderful news @JNJNews @gavi the continent and throughout @CEPIvaccines @WHO & all who made this possible. Citizen 🥏 Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vac & gavi.org or COVID-19 V A DOUBLE VACCINE CRISIS IS ENDANGERING MILLIONS **()**

#### Civil society in Rwanda reaches 60,000 volunteers in ten minutes via 'WhatsApp Trees'

In Rwanda, COVAX had delivered 9 million of the 14 million total vaccine doses received by mid-December 2021. Ensuring access and driving demand for the doses has been high priority, with civil society playing an important role. The 40 member organisations of Rwanda's Civil Society Platform and volunteers from the Rwanda Red Cross Society have been piloting 'WhatsApp Trees' to mobilise volunteers and rapidly share key messaging about COVID-19. Province, district and village volunteers are provided with messaging instructions, which can be shared across the country by approximately 62,000 volunteers within ten minutes.

With 80% of the population reached by mobile phone, and smartphone penetration at 15%, information can be shared very rapidly in Rwanda. With wide geographical reach, the mobile messaging platform offers significant potential to support the uptake of COVID-19 vaccines. The use of innovative approaches by the Government of Rwanda, COVAX partners and civil society has resulted in vaccination rates of up to 100,000 doses per day, including the Pfizer vaccine despite challenging ultra-cold chain and other requirements.



### **COVAX** today

## First billion COVID-19 vaccine doses delivered through COVAX

COVAX has delivered more than one billion doses of COVID-19 vaccines to 144 countries & territories worldwide. It's a key milestone in the largest and most rapid global rollout in history but the world stands at yet another crossroads in our fight against COVID-19.

LEARN MORE >




# We are at an inflection point in the pandemic – and the Gavi COVAX AMC is pivoting accordingly

- The Gavi COVAX AMC must stand ready to help countries respond to the Omicron crisis and mitigate the risks that individual countries cannot manage alone.
- On average, a major new variant has been detected every four months since the WHO characterised COVID-19 as a pandemic.
- It is entirely possible that the next major variant to emerge could be both highly transmissible and cause more severe disease or greater evasion of vaccine immunity – particularly if large swathes of the world remain unvaccinated.
- No one can be certain how supply, demand or disease impact will shift over the next year.
- Plans need to be resilient against multiple scenarios.



### COVAX requires additional upfront financing of at least US\$ 5.2 billion by the end of March 2022


- That funding would provide the Gavi COVAX AMC with the means to pursue a three-pronged strategy:
  - to create a Pandemic Vaccine Pool of a minimum of 600 million additional doses at a cost of at least US\$ 3.7 billion to boost coverage and mitigate against demand and supply risks;
  - to fund critical ancillary costs of dose donations (syringes, safety boxes, no-fault compensation insurance, freight) at a cost of US\$ 545 million; and
  - to build on the Alliance's comparative advantages strengthening in-country delivery systems to get shots into arms with at least US\$ 1 billion for COVAX (US\$ 600 million for Gavi, plus US\$ 400 million that will be raised concurrently by UNICEF).



Gavi

COVAX #BRFAKCOVID

### At least US\$ 3.7 billion of funding will be to secure a Pandemic Vaccine Pool of a minimum of 600 million doses




A 600 Million-dose Pandemic Vaccine Pool could be used to provide...



250 million booster doses to protect 50% of all health workers and the high-risk population of AMC 91 countries

**160 million doses** of new variant-adapted vaccines in case of emergence of immunity-escaping variants



100 million doses to low-income countries to increase primary coverage levels by 13%

Note: examples above are for illustrative purposes



# At least US\$ 545 million of ancillary funding is urgently needed so that donations can continue to deliver impact

- Dose donations are a powerful complement to other COVAX supply and are expected to continue into 2022
- Most donations received by COVAX consist of the COVID-19 vaccines themselves - getting vials of vaccines from donors intousable doses requires extra equipment, logistics and regulatory indemnification.
- Gavi used unallocated Gavi COVAX AMC funds to cover these additional expenses: US\$ 290 million of the more than US\$ 10 billion raised has been earmarked to facilitate donations of the first 650 million doses
- Funding urgently needed for the Gavi COVAX AMC to deliver all doses that donors are now expected to provide through 2022



# At least US\$ 1 billion of support strengthen in-country delivery systems

- Despite recent progress, absorptive capacity in many countries, remains well below levels seen in higher income countries.
- Reducing those gaps in delivery will be critical to achieving equitable access across AMC economies
- Gavi will use these resources to:
  - extend and expand technical assistance through to the end of 2022,
  - fill remaining gaps in countries' cold chain and ultra-cold chain capacity,
  - and replenish its COVID-19 vaccine delivery support envelope given high country demand.





### **Rallying together**



Civil society partners have crucial roles to play, from helping raise awareness in donor capitals about the urgency to continue to mobilise in global solidarity, to supporting last-mile vaccine delivery, particularly with fragile communities and populations and in emergency settings.



#### We are here to support with advocacy tools & resources

#### Partner engagement

- Letters
- High-level messages
- Press releases
- Media interviews
- Op-eds
- Champion appeals

- Newsletters
- Public events
- Blog articles
- Videos
- Social media posts


#### 

The G20 Must Recommit to COVAX



#### **Civil society activities**

- Gavi website
- Multimedia content library
- Key messages
- Social toolkits






## Launching the COVAX AMC Investment Opportunity



## **#COVAX HAS DELIVERED** 1 BILLION #COVID19 VACCINES AROUND THE WORLD!

Join us on January 19th at 3pm CET for a virtual event as we look to 2022 to be the year we close the vaccine equity gap. #breakCOVID

## The path forward



## Q&A

